Previous 10 | Next 10 |
SAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a streamlined leadership structure designed to focus on pipeline advancement and align with Kronos...
2023-12-18 17:22:17 ET More on Kronos Bio Kronos to cut 19% of workforce, focus on drugs KB-0742, lanraplenib Kronos Bio stock slightly up on positive preliminary data for investigational cancer drug Seeking Alpha’s Quant Rating on Kronos Bio Historica...
Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2 New development candidate KB-9558 inhibits the KAT domain of p300 and thereby modulates IRF4, a...
SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical de...
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Norbert Bischofberger, Ph.D., president and chief executive officer, Jorge DiMartino M.D., Ph....
2023-11-20 12:39:18 ET Kronos Bio ( NASDAQ: KRON ) disclosed on Friday that president and chief executive Norbert Bischofberger bought ~1.7M common shares at an average price of $0.96/share for ~$1.47M. Shares of KRON jumped 16.2% on Monday. SEC Filing For fu...
2023-11-20 10:17:26 ET Whether you’re looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week with Thursday’s Thanksgivin...
2023-11-20 08:22:56 ET LogicMark ( LGMK ) +22% . GD Culture Group ( GDC ) +22% Unveils its Transformative and Photorealistic AI-driven Digital Human Technology on TikTok YPF ( YPF ) +19% . Central Puerto ( CEPU ) +17% . Loma Negra ...
Kronos Bio Inc. (KRON) is expected to report $-0.51 for Q3 2023
2023-11-14 02:12:30 ET More on Kronos Bio Kronos to cut 19% of workforce, focus on drugs KB-0742, lanraplenib Kronos Bio stock slightly up on positive preliminary data for investigational cancer drug Seeking Alpha’s Quant Rating on Kronos Bio Historica...
News, Short Squeeze, Breakout and More Instantly...
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that the company would participate i...
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobel...
— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new dose schedule remain on track to open in Q3 2024 —...